Home / Stocks / NBIX

Neurocrine Biosciences (NBIX, Biotechnology) Stock Valuation & Fair Value Quality business with a solid forward outlook

Neurocrine Biosciences (NBIX, Biotechnology) trades at a blended P/E of 22.5, about 74% below its historical normal valuation, with a forward growth estimate of 35.5% and a PEG of 0.63.

DATA AS OF 2026-09-21
Blended P/E
22.5
Normal P/E
85.8
PEG
0.63
Fwd growth
35.5%
Div yield
0.0%
RSI (14)
26.9
Oversold
Technical context
  • Price $139.49 at the 2026-09-23 close, 8.9% below the 20-day average ($153.19) and 13.3% below the 50-day ($160.88).
  • RSI (14) at 26.9.
  • 52-week range $123.10 to $185.50: the price is 24.8% below the high and 13.3% above the low.

The Street vs SeerForecast

Wall Street's mean price target for NBIX is $209.52 across 28 analysts, 50.2% above the current price. The average analyst rating is Strong Buy. Our SeerForecast read of the same stock, formed without analyst targets: quality business with a solid forward outlook. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating has been quality business with a solid forward outlook since 2026-09-19.

Blended P/E and rating by weekBlended P/E moved from 22.5 to 22.5 between 2026-09-19 and 2026-09-21, against a normal P/E of 85.8, with 0 rating changes over 2 recorded weeks.2026-09-19: P/E 22.5, Quality business with a solid forward outlook (recalculated)2026-09-21: P/E 22.5, Quality business with a solid forward outlook40.060.080.0Sep 19Sep 20Sep 21Normal P/E 85.8
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Ratings recorded live since 2026-09-21. Earlier points apply today's valuation rules to the metrics tickerseer archived that week.

WeekBlended P/EPremium to normal P/ERating
2026-09-19P/E 22.5-74%Quality business with a solid forward outlook
2026-09-21P/E 22.5-74%Quality business with a solid forward outlook ← now

Frequently asked questions

Is Neurocrine Biosciences stock overvalued?

At a blended P/E of 22.5 versus its historical normal P/E of 85.8, Neurocrine Biosciences trades about 74% below its typical valuation, with a PEG of 0.63 on 35.5% forward growth. tickerseer currently rates it quality business with a solid forward outlook.

What is Neurocrine Biosciences's fair value and PEG?

Neurocrine Biosciences trades at a blended P/E of 22.5 against a historical normal P/E of 85.8, a PEG of 0.63, and a forward growth estimate of 35.5%.

Has tickerseer's rating of Neurocrine Biosciences changed?

tickerseer's rating has been quality business with a solid forward outlook since 2026-09-19.

What is the analyst price target for Neurocrine Biosciences?

The mean Wall Street price target for Neurocrine Biosciences is $209.52 across 28 analysts, 50.2% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Biotechnology. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track NBIX free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.